Nohaile Michael 4

What Happened Michael Nohaile, a director of Fulgent Genetics, was granted equity awards on May 14, 2026: 5,558 restricted stock units (RSUs) and 8,426 derivative shares (awarded as a derivative/security). Both grants were recorded at $0.00 per share (no cash paid at grant). These are awards (compensation), not open-market purchases or sales.

Key Details

• Transaction date: 2026-05-14; filed with SEC on 2026-05-18 (within the typical 2-business-day reporting window).
• Grant details: 5,558 shares (RSUs) and 8,426 derivative shares; price reported $0.00; total reported value $0.
• Shares owned after transaction: not specified in the provided filing details.
• Footnotes/vesting:
  • F1 (RSUs): Vest over 4 years — 1/4 vests 12 months after May 14, 2026, then 1/16th vests every 3 months over the next 36 months, subject to continued service.
  • F2 (derivative/option): Vest schedule mirrors F1 (4 years total; 1/4 after 12 months; 1/16th every 3 months thereafter), subject to continued service.
• Transaction code: A = Grant/award/other acquisition (compensation).

Context These awards are typical compensation grants to align executive/director incentives with shareholder interests; they are not purchases or sales. The derivative award vests on a schedule (not immediately exercisable/salable); there is no indication of a cashless exercise or immediate sale in this filing. For retail investors, granted awards signal compensation decisions but are not direct market bets by the insider.